Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) Short Interest Down 35.3% in June

Navidea Biopharmaceuticals, Inc. (NYSE:NAVB – Free Report) was the recipient of a large drop in short interest during the month of June. As of June 15th, there was short interest totalling 570,200 shares, a drop of 35.3% from the May 31st total of 881,100 shares. Currently, 4.5% of the company’s shares are short sold. Based […]

Related Keywords

,Navidea Biopharmaceuticals Company Profile ,Therapeutic Development Programs ,Navidea Biopharmaceuticals Inc ,Securities Exchange Commission ,Renaissance Technologies ,Navidea Biopharmaceuticals ,Free Report ,Diagnostic Substances ,Therapeutic Development ,Navidea Biopharmaceuticals Daily ,Nyse Navb ,Navb ,Medical ,Stocks ,Options ,Put ,Call ,